This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design
